Radhika Sarda
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Research Interests
Radhika Sarda has a total of 110 co-authors. Here are the top co-authors by number of shared publications:
- Animesh Ray
All India Institute of Medical Sciences, New Delhi, New Delhi, India
3 shared publications - Sanjeev Sinha
Department of Medicine, All India Institute of Medical Sciences, Ansari Nagar, New Delhi 110029, India
3 shared publications - Arvind Kumar
Department of medicine, All India Institute of Medical Sciences (AIIMS), New Delhi, India
2 shared publications - Manish Soneja
Department of Medicine, All India Institute of Medical Sciences, New Delhi, India
2 shared publications Naveet Wig
Department of Medicine, All India Institute of Medical Sciences, New Delhi, India
2 shared publications- Naveet Wig
Department of Medicine, All India Institute of Medical Sciences, New Delhi, India
2 shared publications
Latest Publications
- Open Access
- 3 November 2026
- Published by Oxford University Press (OUP) in Journal of Antimicrobial Chemotherapy
- Vol. 81 (12)
Real-world experience with cefepime/zidebactam under compassionate use
Introduction: Cefepime/zidebactam is a β-lactam/β-lactam enhancer combination with activity against carbapenem-resistant (CR) Gram-negative pathogens, including metallo-β-lactamase (MBL)-producing organisms. Before regulatory approval, cefepime/zidebactam was available through a compassionate-use programme for patients with CR Gram-negative infections who had limited available treatment options. Methods: We conducted a retrospective, multi-country analysis of patients who received cefepime/zidebactam through compassionate use between 2022 and 2025. Data included demographics, comorbidities, acute complications, prior antibiotic exposure, infection characteristics, microbiology, treatment details, and investigator-assessed outcomes. Results: Eighty-five patients were included (median age 48 years; 57.6% in an intensive care unit at initiation). Primary infections included pneumonia/respiratory infection (30.6%), bone and joint infection (24.7%), and complicated urinary tract infection/pyelonephritis (14.1%). Pseudomonas aeruginosa was the predominant pathogen (77.6%), followed by Klebsiella pneumoniae (14.1%) and Acinetobacter baumannii (11.8%); infections involving at least two Gram-negative pathogens occurred in 10.6%. Among isolates with available genotypic data, MBLs were common and predominantly NDM. The cefepime/zidebactam minimum inhibitory concentration (MIC)50 and MIC90 were 8 and 32 mg/L, respectively. Investigator-assessed clinical success at the end of therapy was achieved in 88.2% of patients (95% CI, 79.7–93.5), and microbiological eradication in 89.4% (95% CI, 81.1–94.3); on-therapy mortality was 10.6% (95% CI, 5.7–18.9). Treatment-emergent adverse events occurred in five patients (5.9%, 95% CI, 2.5–13.0), with one discontinuation. Conclusions: In this uncontrolled compassionate-use case series, cefepime/zidebactam treatment was accompanied by high investigator-assessed clinical success and microbiological eradication in patients with severe infections caused by CR Gram-negative pathogens. These observations require confirmation in prospective controlled studies.
- 3 November 2026
- Published by Oxford University Press (OUP) in Journal of Antimicrobial Chemotherapy
- Vol. 81 (12)
Open AccessReal-world experience with cefepime/zidebactam under compassionate use
Introduction: Cefepime/zidebactam is a β-lactam/β-lactam enhancer combination with activity against carbapenem-resistant (CR) Gram-negative pathogens, including metallo-β-lactamase (MBL)-producing organisms. Before regulatory approval, cefepime/zidebactam was available through a compassionate-use programme for patients with CR Gram-negative infections who had limited available treatment options. Methods: We conducted a retrospective, multi-country analysis of patients who received cefepime/zidebactam through compassionate use between 2022 and 2025. Data included demographics, comorbidities, acute complications, prior antibiotic exposure, infection characteristics, microbiology, treatment details, and investigator-assessed outcomes. Results: Eighty-five patients were included (median age 48 years; 57.6% in an intensive care unit at initiation). Primary infections included pneumonia/respiratory infection (30.6%), bone and joint infection (24.7%), and complicated urinary tract infection/pyelonephritis (14.1%). Pseudomonas aeruginosa was the predominant pathogen (77.6%), followed by Klebsiella pneumoniae (14.1%) and Acinetobacter baumannii (11.8%); infections involving at least two Gram-negative pathogens occurred in 10.6%. Among isolates with available genotypic data, MBLs were common and predominantly NDM. The cefepime/zidebactam minimum inhibitory concentration (MIC)50 and MIC90 were 8 and 32 mg/L, respectively. Investigator-assessed clinical success at the end of therapy was achieved in 88.2% of patients (95% CI, 79.7–93.5), and microbiological eradication in 89.4% (95% CI, 81.1–94.3); on-therapy mortality was 10.6% (95% CI, 5.7–18.9). Treatment-emergent adverse events occurred in five patients (5.9%, 95% CI, 2.5–13.0), with one discontinuation. Conclusions: In this uncontrolled compassionate-use case series, cefepime/zidebactam treatment was accompanied by high investigator-assessed clinical success and microbiological eradication in patients with severe infections caused by CR Gram-negative pathogens. These observations require confirmation in prospective controlled studies.
- Open Access
- 5 August 2022
- Published by SAGE Publications in Journal of Patient Experience
- Vol. 9
Prevalence of Long COVID-19 and its Impact on Quality of Life Among Outpatients With Mild COVID-19 Disease at Tertiary Care Center in North India
Literature is lacking on the spectrum of symptoms of long COVID-19 (defined as symptoms persisting beyond 28 days of diagnosis) and its impact on quality of life. This single-center, cross-sectional study included mild COVID-19 cases as determined by a positive real-time reverse transcription polymerase chain reaction test. Patients were contacted at least 28 days after diagnosis and were interviewed telephonically using semi-structured questionnaires for duration of symptoms, fatigue using Fatigue Severity Scale (FSS) and quality of life using the World Health Organization Quality of Life: Brief Version (WHOQOL-BREF). A total of 251 COVID-19 patients were included; of which 169 (67.3%) were males. The mean age of the patients was 35.8 years (SD = 12.5). The prevalence of long COVID-19 was 28.2% (n = 71, 95% CI: 23.0–34.2). The most common symptoms involved the musculoskeletal system (12.7%), upper respiratory tract (7.6%), and fatigue among 17 (6.8%) patients. Patients with long COVID-19 had significantly higher FSS score and lower WHOQOL-BREF score compared to the patients without long COVID-19 (<28 days).
- 5 August 2022
- Published by SAGE Publications in Journal of Patient Experience
- Vol. 9
Open AccessPrevalence of Long COVID-19 and its Impact on Quality of Life Among Outpatients With Mild COVID-19 Disease at Tertiary Care Center in North India
Literature is lacking on the spectrum of symptoms of long COVID-19 (defined as symptoms persisting beyond 28 days of diagnosis) and its impact on quality of life. This single-center, cross-sectional study included mild COVID-19 cases as determined by a positive real-time reverse transcription polymerase chain reaction test. Patients were contacted at least 28 days after diagnosis and were interviewed telephonically using semi-structured questionnaires for duration of symptoms, fatigue using Fatigue Severity Scale (FSS) and quality of life using the World Health Organization Quality of Life: Brief Version (WHOQOL-BREF). A total of 251 COVID-19 patients were included; of which 169 (67.3%) were males. The mean age of the patients was 35.8 years (SD = 12.5). The prevalence of long COVID-19 was 28.2% (n = 71, 95% CI: 23.0–34.2). The most common symptoms involved the musculoskeletal system (12.7%), upper respiratory tract (7.6%), and fatigue among 17 (6.8%) patients. Patients with long COVID-19 had significantly higher FSS score and lower WHOQOL-BREF score compared to the patients without long COVID-19 (<28 days).
- Open Access
- 6 October 2021
- Published by Elsevier in Diabetes & Metabolic Syndrome: Clinical Research & Reviews
- Vol. 15 (6) , 102308
Impact of metabolic and cardiovascular disease on COVID-19 mortality: A systematic review and meta-analysis
- 6 October 2021
- Published by Elsevier in Diabetes & Metabolic Syndrome: Clinical Research & Reviews
- Vol. 15 (6) , 102308
Open AccessImpact of metabolic and cardiovascular disease on COVID-19 mortality: A systematic review and meta-analysis
- Open Access
- 27 August 2021
- Published by Medknow in Journal of Family Medicine and Primary Care
- Vol. 10 (8) , 3047-3050
Impact of COVID-19 on the patients' income and work in Delhi, India
Background: Currently, there is no data on the impact of COVID-19 on patients' income and work in India. Methods: We conducted a cross-sectional study at a tertiary hospital in New Delhi. We included all the patients who were ≥18 years of age and consecutively diagnosed with COVID-19 between the 1st of May 2020 to 31st July 2020. Patients were interviewed by a physician using a semi-structure questionnaire. Data were collected on socio-economic status, occupation, income loss, leaves taken, decrease in work efficiency (self-perceived) and about-facing any stigma/discrimination at the workplace. Results: Out of 245 patients, 190 patients were employed. A total of 126 patients (66.3%) self-reported their work was affected due to COVID-19 disease. A total of 30.5% of patients (n = 58/190) reported deduction in their salary. The median amount of salary loss was INR 10,000 (IQR 9000–25000). Decrease in income and work efficiency (self-perceived) was found to be 37.3% (n = 71) and 12.1% (n = 23), respectively. A total of 47 patients (37.3%) took personal leaves (median number – 17 days (IQR 14–25), and discrimination/stigma related to the COVID-19 at the workplace was faced by 22.6% of patients. Conclusion: Income and work of a substantial number of patients was affected due to COVID-19, as there was a decrease in income and work efficiency. Patients also had to take personal leaves and face stigma in the workplace. This will inform the policymakers to formulate strategies to mitigate the impact of COVID-19.
- 27 August 2021
- Published by Medknow in Journal of Family Medicine and Primary Care
- Vol. 10 (8) , 3047-3050
Open AccessImpact of COVID-19 on the patients' income and work in Delhi, India
Background: Currently, there is no data on the impact of COVID-19 on patients' income and work in India. Methods: We conducted a cross-sectional study at a tertiary hospital in New Delhi. We included all the patients who were ≥18 years of age and consecutively diagnosed with COVID-19 between the 1st of May 2020 to 31st July 2020. Patients were interviewed by a physician using a semi-structure questionnaire. Data were collected on socio-economic status, occupation, income loss, leaves taken, decrease in work efficiency (self-perceived) and about-facing any stigma/discrimination at the workplace. Results: Out of 245 patients, 190 patients were employed. A total of 126 patients (66.3%) self-reported their work was affected due to COVID-19 disease. A total of 30.5% of patients (n = 58/190) reported deduction in their salary. The median amount of salary loss was INR 10,000 (IQR 9000–25000). Decrease in income and work efficiency (self-perceived) was found to be 37.3% (n = 71) and 12.1% (n = 23), respectively. A total of 47 patients (37.3%) took personal leaves (median number – 17 days (IQR 14–25), and discrimination/stigma related to the COVID-19 at the workplace was faced by 22.6% of patients. Conclusion: Income and work of a substantial number of patients was affected due to COVID-19, as there was a decrease in income and work efficiency. Patients also had to take personal leaves and face stigma in the workplace. This will inform the policymakers to formulate strategies to mitigate the impact of COVID-19.
- Open Access
- 15 July 2021
- Published by Oxford University Press (OUP) in QJM: An International Journal of Medicine
- Vol. 115 (6) , 422
Response to: COVID-19-associated mucormycosis and evolving evidence
We thank Sakthivel et al. for their useful comments on our letter on COVID-19-associated Mucormycosis (CAM). Our article, as noted by them, provides an overview of the plausible pathophysiological mechanisms and likely preponderance of CAM in India. 1
- 15 July 2021
- Published by Oxford University Press (OUP) in QJM: An International Journal of Medicine
- Vol. 115 (6) , 422
Open AccessResponse to: COVID-19-associated mucormycosis and evolving evidence
We thank Sakthivel et al. for their useful comments on our letter on COVID-19-associated Mucormycosis (CAM). Our article, as noted by them, provides an overview of the plausible pathophysiological mechanisms and likely preponderance of CAM in India. 1
- Open Access
Post COVID-19 sequelae: A prospective observational study from Northern India
Background Long COVID, or post-COVID-19 sequelae, is being seen in a growing number of patients reporting a constellation of symptoms, both pulmonary and extrapulmonary. Studies on COVID-19 recovered patients are scarce. Thus, there is a need to add granularity to our existing knowledge about the course and long-term effects of the infection. Aim To describe the clinical details and risk factors of post-COVID sequelae in the North Indian population. Method This prospective observational study was conducted at a tertiary healthcare centre in Northern India between October 2020 to February 2021. Patients aged >18 years with a confirmed COVID-19 disease were recruited after at least two weeks of diagnosis and interviewed for any post-COVID-19 symptoms. Results Of 1234 patients recruited, who were followed up for a median duration of 91 days (IQR: 45-181 days), 495 (40.11%) patients had symptoms. In 223 (18.1%) patients, the symptoms resolved within four weeks, 150 (12.1%) patients had symptoms till twelve weeks, and 122 (9.9%) patients had symptoms beyond twelve weeks of diagnosis of COVID-19. Most common long COVID-19 symptoms included myalgia (10.9%), fatigue (5.5%), shortness of breath (6.1%), cough (2.1%), disturbed sleep (1.4%), mood disturbances (0.48%) and anxiety (0.6%). The major determinants of developing post-COVID-19 symptoms in the patients were hypothyroidism and the severity of the disease. Conclusion Most often, patients complain of myalgias, fatigue, dyspnoea, cough and disturbed sleep. Patients who are hypothyroid or have recovered from moderate to severe COVID-19 are at higher risk of developing post-COVID sequelae. Therefore, a multidisciplinary approach is required to diagnose and manage COVID-19 recovered patients.
Open AccessPost COVID-19 sequelae: A prospective observational study from Northern India
Background Long COVID, or post-COVID-19 sequelae, is being seen in a growing number of patients reporting a constellation of symptoms, both pulmonary and extrapulmonary. Studies on COVID-19 recovered patients are scarce. Thus, there is a need to add granularity to our existing knowledge about the course and long-term effects of the infection. Aim To describe the clinical details and risk factors of post-COVID sequelae in the North Indian population. Method This prospective observational study was conducted at a tertiary healthcare centre in Northern India between October 2020 to February 2021. Patients aged >18 years with a confirmed COVID-19 disease were recruited after at least two weeks of diagnosis and interviewed for any post-COVID-19 symptoms. Results Of 1234 patients recruited, who were followed up for a median duration of 91 days (IQR: 45-181 days), 495 (40.11%) patients had symptoms. In 223 (18.1%) patients, the symptoms resolved within four weeks, 150 (12.1%) patients had symptoms till twelve weeks, and 122 (9.9%) patients had symptoms beyond twelve weeks of diagnosis of COVID-19. Most common long COVID-19 symptoms included myalgia (10.9%), fatigue (5.5%), shortness of breath (6.1%), cough (2.1%), disturbed sleep (1.4%), mood disturbances (0.48%) and anxiety (0.6%). The major determinants of developing post-COVID-19 symptoms in the patients were hypothyroidism and the severity of the disease. Conclusion Most often, patients complain of myalgias, fatigue, dyspnoea, cough and disturbed sleep. Patients who are hypothyroid or have recovered from moderate to severe COVID-19 are at higher risk of developing post-COVID sequelae. Therefore, a multidisciplinary approach is required to diagnose and manage COVID-19 recovered patients.
- Open Access
- 25 November 2020
- Published by Oxford University Press (OUP) in QJM: An International Journal of Medicine
- Vol. 114 (6) , 355-356
COVID-19-associated mucormycosis: an epidemic within a pandemic
India continues to battle the second wave of COVID-19 and has recently reported the highest number of cases ever in a single day from a country. As severe COVID-19 continues to claim thousands of lives in this country, there has also been a recent spate of COVID-19-associated mucormycosis (CAM) cases which have garnered attention globally. More than 14 000 cases of CAM have been reported from all over India with many states resorting to declaration of an epidemic as well as making it a notifiable disease. 1 We wish to elaborate on the evolving situation of CAM in India with special attention to the association of mucormycosis with COVID-19, the pathophysiological basis for CAM, likely reasons for preponderance of CAM in India as well as the core management issues.
- 25 November 2020
- Published by Oxford University Press (OUP) in QJM: An International Journal of Medicine
- Vol. 114 (6) , 355-356
Open AccessCOVID-19-associated mucormycosis: an epidemic within a pandemic
India continues to battle the second wave of COVID-19 and has recently reported the highest number of cases ever in a single day from a country. As severe COVID-19 continues to claim thousands of lives in this country, there has also been a recent spate of COVID-19-associated mucormycosis (CAM) cases which have garnered attention globally. More than 14 000 cases of CAM have been reported from all over India with many states resorting to declaration of an epidemic as well as making it a notifiable disease. 1 We wish to elaborate on the evolving situation of CAM in India with special attention to the association of mucormycosis with COVID-19, the pathophysiological basis for CAM, likely reasons for preponderance of CAM in India as well as the core management issues.